N.P. Iurchenko, N.M. Glushchenko, O.V. Skachkova, I.O. Marchenko, L.G. Buchynska

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine



Summary. Aim: evaluation of DNA ploidy and K-RAS oncoprotein expression in endometrioid endometrial carcinoma (EEC) to determine the metastatic potential of patients with an initial stage of the malignant process. Objects and methods: the study was conducted on samples of postoperative material of 54 patients with EEC stage I according to FIGO (average age: 60.4 years; part from 38 to 72 years). Clinical, morphological, immunohistochemical, flow cytometry, and statistical methods were used for the research. Results: retrospective analysis of medical history revealed patients with EEC who developed metastases in regional lymph nodes within 1.8– 36.6 months. On the basis of this, two groups of studies were formed: I — EEC of patients without metastases (n = 34), II — patients with metastases (n = 20). As a result of the evaluation of the clinical and pathological features of EEC, it was established that G1–G2 tumors predominated (79.4%) in patients of the I group, and in 70.6% of cases, not deep invasion of the myometrium was detected. 55.0% of EEC of the II group had a low degree of differentiation with the deep invasion of the myometrium, which was correlated with a high expression of the oncoprotein K-RAS and the proliferation index. Aneuploidy with iDNA ≥ 2.0 was observed in 20.0% of EEC II group. In such regions, a probably higher expression of K-RAS was determined with this indicator in diploid carcinomas of this group. In addition, the term of occurrence of metastases in patients with aneuploidy was probably shorter than in patients of this group with diploid statuses. Conclusions: it was established that the expression of the K-RAS oncoprotein and DNA ploidy in EEC are associated with the course of the tumor process in stage I patients, which makes it possible to verify patients with a high risk of metastasis.

Keywords: endometrioid endometrial carcinoma, metastasis, K-RAS oncoprotein, DNA content, proliferation index, aneuploidy.




  1. Kotsantis P, Petermann E, Boulton Mechanisms of Onco- gene-Induced Replication Stress: Jigsaw Falling into Place. Cancer Discov 2018; 8 (5): 537–55. doi: 10.1158/2159-8290. CD-17-1461.
  2. Buchynska LG, Glushchenko NM, Nesina IP, et al. Mo- lecular phenotype of high-grade endometrioid carcinoma of the Exp Oncol 2020; 42 (4): 300–5. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15450.
  1. Ngoi NYL, Sundararajan V, Tan Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int J Gynecol Cancer 2020; 30 (8): 1224–38. doi: 10.1136/ ij 1277.
  2. Cáceres-Gutiérrez RE, Alfaro-Mora Y, Andonegui MA, et al. The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Front Cell Dev Biol 2022; 10: 751367. doi: 10.3389/fcell. 2022.751367.
  3. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ ESP guidelines for the management of patients with endo- metrial c Int J Gynecol Cancer 2021; 31 (1): 12–39. doi: 10.1136/ij 30.
  4. Rabban JT, Gilks CB, Malpica A, et al. Issues in the Differ- ential Diagnosis of Uterine Low-grade Endometrioid Carci- noma, Including Mixed Endometrial Carcinomas: Recom- mendations from the International Society of Gynecological P Int J Gynecol Pathol 2019; 38 (1; Suppl 1): S25–S39. doi:  10.1097/PGP.0000000000000512.
  5. Movchan OM, Svintsitskiy VS, Tsip NP, et al. Features of recurrence of endometrioid type endometrial cancer of I Exp Oncol 2021; 43 (4): 365–9. doi: 10.32471/ exp-oncology.2312-8852.vol-43-no-4.17052.
  6. Buchynska Endometrial cancer: taxonomy of genetic changes of tumor cells and their role in determination of malignant potential: Abstract of the D.Sc. Dissertation (speciality 14.01.07 — oncology). R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, 2012. 34 p. (in Ukrainian).
  7. Iurchenko NP, Glushchenko NM, Buchynska Assessment of DNA status and peculiarities of expression of cyclins D1, E and transcription factor E2F1 in cells of epithelial endometri- al tumors. Oncology 2019, 21 (3): 230–7 (in Ukrainian). doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.7783.
  8. Song T, Lee J-W, Kim H-J, et al. Prognostic significance of DNA ploidy in stage I endometrial cancer. Gynecol Oncol 2011; 122 (1): 79–82. doi: 11016/j.ygyno.2011.03.017.
  9. Pradhan M, Abeler VM, Danielsen HE, et al. Prognostic im- portance of DNA ploidy and DNA index in stage I and II en- dometrioid adenocarcinoma of the endometrium. Ann Oncol 2012; 23 (5): 1178–84. doi: 11093/annonc/mdr368.
  10. Banno K, Yanokura M, Iida M, et al. Carcinogenic mecha- nisms of endometrial cancer: involvement of genetics and J Obstet Gynaecol Res 2014; 40 (8): 1957–67. doi: 10.1111/jog.12442.
  11. Sideris M, Emin EI, Abdullah Z, et al. The Role of KRAS in Endometrial Cancer: A Mini-Review. Anticancer Res 2019; 39 (2): 533–9. doi: 121873/anticanres.13145.
  12. Kurman RJ, Carcangiu ML, Herrington CS, Young WHO classifi ation of tumours of female reproductive or- gans. Lyon: IARC 2014: 307 p.
  13. Al Zubaidi T, Gehrisch OHF, Genois MM, et al. Targeting the DNA replication stress phenotype of KRAS mutant cancer Sci Rep 2021; 11 (1): 3656. doi: 10.1038/s41598-021- 83142-y.
  14. Cáceres-Gutiérrez RE, Alfaro-Mora Y, Andonegui MA, et al. The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Front Cell Dev Biol 2022; 10: 751367. doi: 10.3389/fcell. 2022.751367.
  15. Birkeland E, Wik E, Mjøs S, et al. KRAS Gene Amplification and Overexpression but Not Mutation Associates with Agg- ressive and Metastatic Endometrial Canc Br J Cancer 2012; 107 (12): 1997–2004. doi:10.1038/bjc.2012.477.
  16. Xu J, Huang L, Li DNA aneuploidy and breast cancer: a meta-analysis of 141,163 cases. Oncotarget 2016; 7 (37): 60218–29. doi: 10.18632/oncotarget.11130.
  1. Pattheya A, Bomanb K, Tavelinb B, et al. Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial car- c Acta oncol 2021; 60 (9): 1218–24. doi:10.1080/ 0284186X.2021.1939146.
  2. Bell DW, Ellenson Molecular Genetics of Endome- trial Carcinoma Annu Rev Pathol 2019; 14: 339–67. doi: 10.1146/annurev-pathol-020117-043609.
  3. Kreis NN, Louwen F, Yuan The Multifaceted p21 (Cip1/ Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy. Cancers (Basel) 2019; 11 (9): 1220. doi: 10.3390/cancers11091220.
  4. Felix AS, Sherman ME, Hewitt SM, et al. Cell-cycle protein expression in a population-based study of ovarian and en- dometrial canc Front Oncol 2015; 5: 25. doi: 10.3389/ fonc.2015.00025.
  5. Bhagat R, Kumar SS, Vaderhobli S, et al. Epigenetic al- teration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Tumour Biol 2014; 35 (9): 9069–78. doi: 10.1007/s13277-014-2136-1
  1. Salo-Mullen EE, O’Reilly EM, Kelsen DP, et al. Identifica- tion of germline genetic mutations in patients with pancre- atic Cancer 2015; 121 (24): 4382–8. doi: 10.1002/ cncr.29664
  2. Feng W, Han Z, Zhu R, et al. Association of p16 gene methy- lation with prostate cancer risk: a meta-analysis. J BUON 2015; 20 (4): 1074–80. PMID:
  3. Nesina IP, Iurchenko NP, Buchynska LG. Мarkers of the epitelial-mesenchemical transition in the cells of endo- metrial c Exp Oncol 2018; 40 (3): 218–22. doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.7783.
  4. Ribatti D, Tamma R, Annese T. Epithelial-Mesenchy- mal Transition in Cancer: A Historical O Transl Oncol 2020; 13 (6): 100773. doi: 10.1016/j.tranon.2020. 100773.

No comments » Add comment